Figure 1: Epithelial CYLD suppresses AOM/DSS-induced colon tumorigenesis.
From: The tumour suppressor CYLD regulates the p53 DNA damage response
(a) CYLDΔ932mye and CYLDΔ932FL male littermates were injected with 10 mg kg−1 AOM followed by two cycles of treatment with 2% DSS. (b) Graph showing body weight. (c) Quantification of murine endoscopic index of colitis severity (MEICS) on the indicated days. (d) Graph showing colon tumour numbers on day 65. One representative out of two independent experiments is shown. (e) CYLDΔ932IEC and CYLDΔ932FL male littermates were injected with 7.5 mg kg−1 AOM followed by one cycle of treatment with 2% DSS. (f) Graph showing body weight. (g) MEICS on the indicated days. (h) Representative endoscopy images and graph showing colon tumour numbers. One representative out of five independent experiments is shown. (i) Representative Hematoxylin and Eosin (H&E) stained distal colon sections on day 60 from the indicated AOM/DSS-treated mice. Scale bars, 2,500 and 50 μm. (j) Graphs showing the incidence of low-grade intraepithelial neoplasia (D1/D2) and high-grade intraepithelial neoplasia/carcinoma in situ (D3/Cais), and the cumulative size of high-grade intraepithelial neoplasia/carcinoma in situ D3/(Cais) in the indicated AOM/DSS-exposed mouse lines. The evaluated samples comprise specimens from experiments shown in Fig. 1e–h and Supplementary Fig. 2a–d. For all experiments, data are shown as mean±s.d. Statistical significance was determined with Student’s t-test; *P≤0.05, ***P≤0.0005.
